Efficiently inform chemical structure-activity relationship (SAR) studies by providing rapid, predictive data on key liabilities, thereby guiding molecular modification and subsequent synthesis endeavors.
Creative Biolabs offers a comprehensive range of tailored in vitro ADME services, including professional testing design, GLP-based in vitro ADME testing, and data analysis, to help you characterize the ADME properties of your drug candidate and its interaction function. Our high-throughput ADME screening platforms provide rapid and efficient testing capabilities to ensure the highest level of precision, reproducibility, and consistency in our results. Our experienced team has strong problem-solving skills that enable us to perform a variety of in vitro ADME screening tests and assist clients in coming up with a solution that suits their drug discovery needs.
In vitro ADME studies are foundational to modern drug discovery, providing controlled, mechanistic data on how a compound interacts with biological systems outside of a living organism. Performing early in vitro ADME test is a way to better understand the absorption, distribution, mode of action (MOA), metabolism, excretion (ADME), and pharmacokinetic (PK) properties of a compound. These properties are very critical for selecting the proper drug candidates for later experiments.
Inquire regarding partnership potential - Request a consultation.
Fig.1 The Principles of ADME.
Efficiently inform chemical structure-activity relationship (SAR) studies by providing rapid, predictive data on key liabilities, thereby guiding molecular modification and subsequent synthesis endeavors.
Proactively identify compounds with poor predicted bioavailability or high metabolic instability, significantly reducing the probability of failure during expensive in vivo and costly clinical development phases.
Utilize robust In Vitro- In Vivo extrapolation (IVIVE) models, derived from comprehensive metabolic and binding data, to forecast human systemic clearance and appropriate initial human dosing strategies.
Determine the unbound drug fraction through plasma and tissue protein binding assays, allowing for a more accurate assessment of the concentration available at the intended therapeutic target site.
Our HTS platforms are engineered for the rapid and efficient processing of a substantial volume of samples. This capability dramatically streamlines the drug discovery timeline and enables accelerated prioritization of lead candidates.
Advanced automation and validated systems ensure the delivery of results that are consistently accurate, highly reproducible, and rigorously reliable. This technological rigor provides dependable data for critical development decisions.
Creative Biolabs offers fully customizable services to meticulously align with unique project specifications and diverse therapeutic modalities. We tailor assay parameters to meet specific client needs throughout the discovery process.
Our team of experienced scientists furnishes comprehensive technical assistance, offering guidance on experimental design, data analysis, and expert interpretation to facilitate strategic project advancement.
Initiate partnership - Submit a quotation request.
A: Early integration of initial screening is advised during lead identification to proactively assess risks. This ensures resources are focused on compounds with optimal properties, resulting in considerable cost and time savings.
A: Whole liver cells offer a physiologically comprehensive model, measuring total compound clearance via both major and minor metabolic pathways. This facilitates more precise prediction of systemic drug disposition than simpler cellular components.
Provides quantitative measurement of drug concentrations and metabolites in complex biological matrices using high-resolution mass spectrometry platforms.
Learn More →Offers expertise in formulating compounds for in vivo administration and assessing the physical/chemical stability of the drug product.
Learn More →Creative Biolabs' years of expertise and proprietary LC-MS-based technologies enable us to gain insight into your ADME analysis development, accelerate your data collection, and help you interpret the results. We are devoted to accelerating and enhancing your drug discovery, allowing you to identify the most promising hit compounds for the next immunotherapy-based cancer treatment.
For more information, please contact us.